Gwangju, South Korea

Darren R Williams

This inventor holds 6 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Gwangju Institute of Science and Technology, Chonnam National University, Unique Medicare Co., Ltd.. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Darren R Williams. Retrieved from https://idiyas.com/inventor/darren-r-williams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 33.3

 

Average Co-Inventor Count = 3.8

ph-index = 1


Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Darren R Williams

Introduction

Darren R Williams is a notable inventor based in Gwangju, South Korea. He has made significant contributions to the field of science and technology, particularly in the area of muscle atrophy and cell reprogramming. With a total of 6 patents to his name, Williams is recognized for his innovative approaches to complex biological challenges.

Latest Patents

One of his latest patents is a composition comprising an organoselenium compound for the treatment of skeletal muscle atrophy. This application relates to a composition designed to prevent, treat, and improve skeletal muscle atrophy, which includes an organoselenium compound. The composition has shown promise in recovering the thickness of muscle fibers reduced by dexamethasone treatment. Additionally, in a muscle loss model involving mice, the composition demonstrated an ability to reduce damaged muscle and restore muscle mass. This suggests that the composition could be effectively utilized for the treatment, prevention, or improvement of muscle atrophy.

Another significant patent by Williams is a composition for inducing cell reprogramming. This invention involves an indazole derivative compound that exhibits an improved biological profile and can efficiently perform cell reprogramming. Unlike conventional compounds used for inducing low-molecular cell reprogramming, the indazole derivative compound does not exhibit cytotoxicity. This characteristic positions it favorably in the market for cell therapy products when applied clinically. The compound of the present invention has shown a remarkable ability for cell reprogramming while maintaining minimal cytotoxicity.

Career Highlights

Darren R Williams has worked with esteemed institutions such as the Gwangju Institute of Science and Technology and Chonnam National University. His work in these organizations has contributed to his development as a leading figure in his field.

Collaborations

Williams has collaborated with notable colleagues, including Da-Woon Jung and Ji-Hyung Lee. These partnerships have likely enhanced his research and innovation capabilities.

Conclusion

Darren R Williams stands out as an influential inventor whose work addresses critical issues in muscle atrophy and cell reprogramming. His innovative patents reflect his commitment to advancing scientific knowledge and improving therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…